Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Will CNS Drug Development Go In 2018?

Executive Summary

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

You may also be interested in...



CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

2020 VC Landscape: Reviewing The First Six Months

A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June. 

Alzheimer’s Is Not A Silent Disease If You Are Listening

Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel